Cartalax

A tiny peptide said to remind ageing cartilage cells how to repair themselves. The evidence stops at the lab dish.

Evidence: ELab & animal what's this?
Grade E. Cell culture only, from essentially one research lineage.
Also known as: AED peptide · Kartalax
Class: Short synthetic Khavinson bioregulator, cartilage-directed. Exact sequence disputed.

The 30-second version

WhatA short peptide built on Ala-Glu-Asp, with versions sold as a three- or four-amino-acid sequence.

Why people use itJoint and cartilage support, in short pulsed courses.

The honest catchNo human trial, and it’s unclear whether it even reaches cartilage, which has no blood supply.

What it is

Cartalax is one of the St Petersburg "bioregulators", a family of very short peptides each aimed at one tissue. Its relatives here are Epitalon and Pinealon. Its identity is disputed. Some sources define it as the tripeptide AED, others sell a four-residue version, and a few confuse it with Epitalon’s sequence. A buyer often can’t be sure which molecule is in the vial.

How it’s proposed to work

Enters the cell, small enough in theory to reach the nucleus.

Touches DNA regulatory regions and nudges genes on or off (the bioregulator theory).

Chondrocytes turn their collagen and aggrecan genes back up.

Self-repair. Reminds the cell to repair rather than forcing a response.

The problem. Very short peptides break down in blood within minutes, and cartilage has no blood supply.

What the research shows

In the lab: in ageing human stem-cell cultures, AED raised IGF1 gene expression about 3.5–5.6-fold and shifted other ageing-related genes¹. A 2023 review grouped AED with short peptides studied for steering stem cells toward cartilage². In animals and people: no solid independent animal work, and no human trial.

A gene-expression change in a dish is a long way from rebuilding a human joint. Experiencing no noticeable change fits what is known.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Cartilage and joints	ELab & animal	Studied for cartilage-cell regulation²	Cell culture, one lineage	Unproven
Gene expression	ELab & animal	IGF1 up 3.5–5.6× in ageing stem cells¹	A dish, not a joint	Preliminary
Reaches cartilage	ELab & animal	Theoretical	Delivery unresolved	Speculative

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Published human	None	—	—
Community	~1–2 mg/day in short pulsed courses, repeated periodically	Subcutaneous (or oral courses)	D

Preparing & storing

Dissolves in bacteriostatic water. Keep the powder cool and dark, refrigerate once mixed and handle gently.

Reported side effects

Mild injection-site redness
Most reports describe no noticeable effect, good or bad

The real risks are the unknowns: human safety, and whether the vial holds the molecule that was studied.

Who should avoid it

Active or past cancer: it raised IGF1 expression, a growth signal
Pregnancy and breastfeeding
Anyone wanting evidence-backed joint support

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Not approved	Research use only.
EMA (EU)	Not approved	—
CDSCO (India)	Not approved	—
WADA	Not named	S0 could apply.

The NexGen read

The thinnest evidence in the Youth section

Cartalax rests on cell-culture work from one research lineage, an unproven mechanism and a delivery problem. Set expectations very low, and make sure any supply is identity-tested.

References

Ashapkin V, Khavinson V, Shilovsky G, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323–4329.
Linkova N, Khavinson V, Diatlova A, et al. Peptide regulation of chondrogenic stem cell differentiation. Int J Mol Sci. 2023;24(9):8415.
Khavinson VK, Popovich IG, Linkova NS, et al. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053.